Friday, January 21, 2022

Dr Reddy’s Laboratories

Sauri Gudlavalleti joins Sai Life Sciences as COO

Hyderabad: Hyderabad-based Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), appointed Sauri Gudlavalleti as its chief operating officer. Sauri will report...

Granules India appoints Dr KVS Ram Rao as CEO

Hyderabad: Hyderabad-based pharmaceutical company Granules India appointed Dr KVS Ram Rao as joint managing director & CEO with effect from January 05, 2022. Dr...

Granules appoints former Dr Reddy’s CFO as independent director

Hyderabad: Hyderabad-based Granules India, a vertically integrated pharmaceutical company, appointed Dr Saumen Chakraborty as non-executive independent director on the Board of the company with...

Dr Reddy’s, Prestige BioPharma partner to commercialise Trastuzumab biosimilar for cancer treatment

Hyderabad: Hyderabad-based Dr Reddy’s Laboratories and Prestige BioPharma have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of...

Hyderabad startup Darwinbox automating HR for large firms

Hyderabad: What could large enterprises like Adani Wilmar, Swiggy and JSW have in common? They all use the same HR technology platform that has...

Dr Reddy’s Q2 net profit up 30%

Hyderabad: Hyderabad-based Dr Reddy’s Laboratories reported a consolidated profit after tax (PAT) of Rs 992 crore for the quarter, up 30 per cent from...

Dr Reddy’s sets Guinness record title with ‘Fastminar’

Hyderabad: Dr Reddy’s Laboratories created ‘Fastminar’, the world’s largest toothbrush sculpture of a body part dedicated to raising awareness of dentin hypersensitivity. Fastminar is...

Dr Reddy’s enters into definitive agreement with Citius Pharmaceuticals

Under the terms of agreement, Dr Reddy’s will receive $40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the CTCL (cutaneous T-cell lymphoma)

Dr Reddy’s launches cancer drug in Canada

Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.

Dr Reddy’s to sell US, Canada rights for migraine drug to BioDelivery Sciences 

Under the terms of agreement, Dr Reddy’s will receive $6 million (about Rs 45 crore) upfront upon closing, followed by $9 million (over Rs 65 crore) one year from closing.

India-made Sputnik V vax to be available during Sept-Oct: Dr Reddy’s

Hyderabad firm expects that the availability of imported vaccine doses will ease from August onwards to accelerate vaccination

Dr Reddy’s, ICICI Lombard partner to pilot launch cashless digital health solution

Multi-service mobile app platform brings together doctors, laboratories & diagnostics, pharmacies, and insurance for a one-stop cashless and seamless outpatient user experience

Dr Reddy’s Q1 net profit falls 1.5pc to Rs 570.8 crore

The company's revenues increased by 11.4 per cent year-on-year to Rs 4,919.4 crore in Q1FY22 from Rs 4,728.4 crore in Q1FY21.

Hyderabad firms dominate bulk drugs sector

Demand for Covid pandemic-related drugs will continue to drive the growth momentum this fiscal

Dr Reddy’s to strengthen commercial roll-out of Sputnik V in coming weeks

Soft launch of Sputnik V vaccine reaches over 50 cities and towns, after initial launch in Hyderabad on May 14

Latest News

- Advertisement -